Table 1. Key results of cost analysis: cost per patient

Costs	Gilteritinib	Sorafenib	Difference
Medicine acquisition cost	¶¶	¶¶	¶¶
Relapse treatment cost	£0	£4,769	−£4,769
Medicine administration cost	£498	£509	−£11
Adverse event cost	£1,700	£1,522	£178
Other secondary care costs	¶¶	¶¶	¶¶
Total cost	¶¶	¶¶	¶¶
¶¶ Commercial in confidence data removed			